BioPorto (OTC:THOXF, NASDAQ COPENHAG:BIOPO) A/S Chief Medical Officer Christopher Bird spoke to Proactive New York about the Danish group's interim analysis of data from the pediatric clinical trial being conducting to evaluate The NGAL Test as a tool for risk assessment of moderate to severe acute kidney injury.
Bird says he believes the final results will provide strong support for the value of The NGAL Test as a biomarker to identify risk of AKI in critically ill children. The interim analysis includes data collected from six different leading US children’s hospitals over a twelve-month period.
BioPorto (NASDAQ COPENHAG:BIOPOR) intends to continue expanding patient enrollment in order to maximize the study’s statistical power for the upcoming US Food & Drug Administration (FDA) submission.